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Distinguishing N-acetylneuraminic acid linkage
isomers on glycopeptides by ion mobility-mass
spectrometry†
H. Hinneburg,‡ab J. Hofmann,‡bc W. B. Struwe,d A. Thader,e F. Altmann,e
D. Varo´n Silva,a P. H. Seeberger,ab K. Pagel*bc and D. Kolarich*a
Diﬀerentiating the structure of isobaric glycopeptides represents amajor
challenge for mass spectrometry-based characterisation techniques.
Here we show that the regiochemistry of the most common
N-acetylneuraminic acid linkages of N-glycans can be identified in a
site-specific manner from individual glycopeptides using ion mobility-
mass spectrometry analysis of diagnostic fragment ions.
Protein glycosylation as post-translationalmodification tremendously
influences cellular events such as cell–cell interactions and receptor
recognition.1,2 Glycosylation is highly dynamic, cell-type specific and
depends on a variety of additional factors such as the developmental
status of the cell.3,4 Understanding the impact of glycosylation on
protein function requires detailed knowledge of individual glycan
structures and their site-specific distribution, as glycoprotein macro-
and microheterogeneity can vary tremendously within a single
protein.5–9 Therefore, knowledge of both individual glycan structure
and the location on a given protein is important in revealing these
complex structure–function relationships.6
Liquid chromatography-mass spectrometry (LC-MS) is a very
sensitive technique that is widely used for studying site-specific
protein glycosylation.5,7,9,10 Diﬀerentiation of minor changes in
glycan structure, such as terminal N-acetylneuraminic acid (NeuAc)
linkages, directly from glycopeptides is very challenging due to
limits in LC separation and the isobaric nature of the fragments
observed by MS.7,10 A promising technique capable of providing
additional structural information is ion mobility spectrometry (IM)
coupled to mass spectrometry (IM-MS).11 In IM, analyte ions
travel through a cell filled with an inert neutral gas aided by a
weak electric field and undergo a series of low-energy collisions
with the gas. Compact ions undergo fewer collisions with the
drift gas than more extended ions and therefore traverse the IM
cell faster. As a result, in IM-MS molecular ions or their
fragments are not only separated according to their mass and
charge, but also according to their size and shape, which
enables the separation of isomers. The obtained drift times
can be converted into rotationally-averaged collision cross
sections (CCSs),12,13 which are absolute biophysical properties
that can be used for structural classification by reference to
database values.14
IM-MS studies on isolated glycan isomers show great pro-
mise,15–19 however, very few reports focus on isomeric glyco-
peptides.18,20 Here we report a universally applicable and rapid
approach capable of differentiating a2,3 and a2,6 NeuAc linkages in
N-glycopeptides without any additional sample preparation steps.
Using IM-MS we evaluated a small set of well-defined, synthetic
glycopeptides carrying N-glycans containing either a2,3 or a2,6
linked NeuAc residues. To illustrate the robustness of the method,
we tested complex mixtures using two forms of a-1 proteinase
inhibitor (A1PI) produced in different cell types.
Homogeneous glycopeptides were generated by chemical and
chemo-enzymatic synthesis for systematic IM-MS method develop-
ment. An asparagine (Asn) building block carrying biantennary,
mono- or disialylated N-glycans was obtained from egg yolk
using a combination of extraction and proteolytic digestion
steps (for details see ESI†).21,22 This glycan-Asn building block
was Fmoc protected, the NeuAc residues benzylated and the
molecule subsequently used to synthesize N-glycopeptides by
solid-phase peptide synthesis (SPPS).
The first set of glycopeptides was designed based on the
naturally occurring tryptic peptide sequence from human
butyrylcholinesterase (505YGNPNETQNNSTSWPVFK522, UniProt
entry P06276).23 This peptide contains three possible glycosylation
sites (boldface) defined by the consensus sequence N-X-T/S/C
(X a P), two of which are glycosylated in serum.23 To reduce
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complexity, the sequence was simplified to YGNVNETQNNSFK
and an a2,6 disialylated, biantennary glycan was selectively
incorporated by SPPS at one glycosylation site, either near the
N-(GP1) or near the C-terminus (GP2). IM-MS experiments were
performed to determine whether the method can separate the
isobaric glycopeptides. As protonated ions, both isomers,
regardless of the charge state, could not be separated and
showed identical drift times (Fig. S4, ESI†). However, when
quadruply deprotonated ions ([M  4H]4 = 928) were measured,
GP1 andGP2 had noticeably diﬀerent drift times of 5.80 and 5.33ms
(Fig. 1). Both isomers, when examined as mixtures, were nearly
baseline separated illustrating that IM-MS can in principle be
used to diﬀerentiate isobaric glycopeptides that merely diﬀer in
their glycosylation site.
Next, we examined two glycopeptides with a single glycosylation
site but diﬀerent glycan structures. Specifically, the attached
complex-type glycans diﬀered in the linkage of the terminal
NeuAc residue, that is either a2,3- or a2,6-linked to galactose.
Subtle diﬀerences in NeuAc regiochemistry are of biological
and biopharmaceutical importance8,24 and are challenging to
characterise using established glycoproteomics techniques.25,26
The investigated peptides are designed based on the human protein
C fragment 284EVFVHPNYSK293 (UniProt entry P04070) that contains
one glycosylation site (boldface). The peptide was synthesized by
SPPS using an Asn building block containing an a2,6 mono-
sialylated, biantennary N-glycan. Subsequently, a fraction of the
resulting glycopeptide (GP3) was desialylated using trifluoroacetic
acid followed by enzymatic re-sialylation using recombinant
b-galactoside a2,3-sialyltransferase 3 (see ESI†). Finally, a glycopeptide
(GP4) exclusively carrying a2,3 linked NeuAc residues was obtained.
Only marginal, non-significant drift time diﬀerences between
GP3 and GP4 were observed for 3+ molecular ions of the intact
glycopeptides such that they cannot be separated in mixtures
(Fig. 2b). Given the minor structural diﬀerences in the glycan
moiety compared to the overall size of the molecule this result
was not surprising.
When collision-induced dissociation (CID) is applied to
positively charged glycopeptide ions, glycosidic cleavages are
the preferred fragmentation pathway resulting in a multitude of
oligosaccharide-only fragment ions (B- and Y-type fragments in
Fig. 2).¶ 27 Tandem MS analysis of GP3 and GP4 yielded almost
identical CID fragment spectra and did not provide diagnostic
information for any glycan structural features (Fig. 2a). How-
ever, from these oligosaccharide-only fragment ions them/z 657
B3 type fragment is of particular interest because this oxonium
ion corresponds to a trisaccharide consisting of Gal, GlcNAc
and NeuAc residues in N-glycopeptides. To elucidate whether
regiochemical diﬀerences of the NeuAc linkage in GP3 and GP4
leads to drift time diﬀerences of the resulting fragments, CID
experiments were followed by IM-MS analysis. The extracted
arrival time distributions (ATDs) of these m/z 657 B3 ions were
vastly diﬀerent for GP3 and GP4 (Fig. 2b), with the a2,6
fragment exhibiting a considerably shorter drift time when
compared to the a2,3 equivalent. When both glycopeptides
were mixed, the isomeric NeuAc-containing fragments showed
baseline separation. In addition, the collision cross sections in
nitrogen drift gas (TWCCSN2) of 236 Å
2 for the a2,6 linked NeuAc
and 246 Å2 for the a2,3 linked NeuAc fragments diﬀered about
4%, well above the 1.5% error of the method.13 These values are
highly diagnostic to the regiochemistry of the underlying
NeuAc linkage and can be used to gain site-specific information
on important glycan structural features directly from individual
glycopeptides in a single experiment.
To evaluate whether similar diagnostic fragments could be
obtained from complex mixtures within a glycoproteomics
workflow, forms of the glycoprotein A1PI were tested (Fig. 3a).
N-Glycan NeuAc linkages on A1PI diﬀer depending on the
biological source of the protein. Human plasma A1PI contains
mostly a2,6 linked NeuAc residues25 whereas the same protein
recombinantly expressed in Chinese hamster ovary (CHO) cells
only contains a2,3 sialylated glycans.28 A1PI samples from both
sources were purified using SDS-gel electrophoresis followed by
in-gel tryptic digestion and glycopeptide enrichment using hydro-
philic interaction chromatography (HILIC) to remove unglycosylated
peptides as these can suppress eﬃcient glycopeptide detection
(for details see ESI†).22 Subsequently, the purified glycopep-
tides were analysed oﬀ-line by IM-MS (Fig. S5 and S6, ESI†).
Known glycopeptide precursor ions25 were m/z-selected for
tandem IM-MS experiments and characteristic B3 fragments
were observed after CID (Fig. 3b). Importantly, the drift times of
the obtained B3 fragments of 7.03 ms (from CHO precursor m/z
1273 and 1401) and 6.44 ms (from human plasma precursorm/z
1321) were essentially identical to those observed for the
synthetic glycopeptides GP4 (6.96 ms) and GP3 (6.38 ms),
respectively. In addition, the TWCCSN2 of the oxonium fragment
ions (Fig. 3b) were consistent with the synthetic reference
Fig. 1 IM-MS separation of the isobaric glycopeptides GP1 and GP2. Two
isomeric glycopeptides that share the same sequence and attached
glycan, but diﬀer in the site of glycan attachment can be distinguished
based on their drift time (top and middle) and separated in mixtures
(bottom) when analysed as quadruply deprotonated ions.§
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Fig. 3 Regiochemistry analysis of N-acetylneuraminic acid (NeuAc) linkages in a1-proteinase inhibitor (A1PI). (a) A1PI isolated from human plasma
and recombinantly expressed in Chinese hamster ovary (CHO) cells was purified, digested with trypsin, and the glycopeptides HILIC-enriched.
(b) Fragmentation of the obtained glycopeptides and subsequent IM-MS analysis of the characteristic B3-trisaccharide fragments (m/z 657) enabled
the diﬀerentiation of a2,3 from a2,6 linked NeuAc. The observed fragment drift times and TWCCSN2 are independent of the underlying precursor
sequence.§
Fig. 2 Diﬀerentiation of N-acetylneuraminic acid (NeuAc) linkage isomers using CID fragmentation and subsequent IM-MS analysis. Two isomeric
glycopeptides, which either carry a2,6 (GP3) or a2,3 (GP4) linked NeuAc were analysed. (a) Both peptides exhibit identical MS/MS spectra, as shown
for the triply protonated precursor ion (red).¶ (b) When analysed as mixture the intact glycopeptide ions cannot be separated by IM-MS (m/z 991, red).
B3-trisaccharide fragments (m/z 657, blue) directly cleaved from the glycopeptide by CID on the other hand show characteristic drift times depending on
the regiochemistry of the NeuAc linkage, which allows unambiguous identification a2,3 and a2,6 linked isoforms.§
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glycopeptide data and can be used to diﬀerentiate a2,3 from
a2,6 sialylated N-glycans from all sialylated glycopeptides
obtained from CHO-derived and human A1PI (Fig. 3b). The
universal applicability of this approach is demonstrated, as size
and sequence of the glycopeptide precursors did not aﬀect the
drift time of the resulting B3 fragment. This finding underscores
the diagnostic nature of the a2,3 or a2,6 fragments and justifies
this approach as a reliable fragment-based method to obtain
N-glycan structure information directly from glycopeptides.
In conclusion, we show that IM-MS can significantly improve
the identification of isomeric glycopeptides and fits seamlessly
within existing glycoproteomics workflows. Peptides with two
distinct glycosylation sites can be diﬀerentiated directly as intact
molecular ions using IM-MS. The regiochemistry of the prevalent
a2,3 and a2,6 NeuAc linkages in N-glycosylated peptides can be
distinguished and allows for the unambiguous identification in
a site-specific manner on basis of the CCSs of diagnostic B3-type
fragments that are cleaved directly from mass-selected glycopeptide
precursors. The approach is fast, does not require derivatisation and
is universally applicable regardless of the nature of the investigated
glycoprotein. Our data highlight the immense potential of IM-MS to
be implemented into existing glycoproteomic workflows.
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